Glucotrack, Inc.
For the period ended Sep 30, 2025. Filed Nov 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 13, 2025
GCTK$1.39-32.2%Stored close · as of Oct 29, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| Nine-month period ended September 30, | ||
|---|---|---|
| 2025 | 2024 | |
| (Unaudited) | ||
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||
| Loss for the period | $(15,760) | $(12,503) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 28 | 22 |
| Stock-based compensation | 121 | 239 |
| Issuance of restricted shares as compensation towards directors | - | 178 |
| Linkage difference on principal of loans from stockholders | - | 1 |
| Revaluation expenses incurred from settlement of financial liabilities | 1,505 | |
| Revaluation expenses related to derivative financial liabilities | 2 | |
| Change in fair value of derivative liability | 3,269 | |
| Amortization of debt discount and interest expense related to promissory notes | 5 | 330 |
| Amortization of original issue discount related to promissory note | 31 | - |
| Loss on warrant repurchase | 99 | - |
| Changes in assets and liabilities: | ||
| Other current assets | (86) | 80 |
| Accounts payable | 717 | 1,129 |
| Other current liabilities | 272 | 26 |
| Net cash used in operating activities | (11,304) | (8,991) |
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||
| Purchase of property and equipment | (76) | (104) |
| Net cash used in investing activities | (76) | (104) |
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||
| Net proceeds from underwritten U.S. public offerings (Note 3A) | 10,715 | - |
| Net proceeds from promissory note | 3,000 | |
| Series A warrant repurchase | (166) | - |
| Issuance of convertible promissory notes and bifurcated conversion feature through private placement transaction | - | 360 |
| Issuance of convertible promissory note, bifurcated conversion and redemption features and detachable warrants through private placement transaction | - | 4,000 |
| Issuance of notes and warrants through private placement transaction | - | 100 |
| Net proceeds from private placement transaction | - | 500 |
| Net cash provided by financing activities | 13,549 | 4,960 |
| Effect of exchange rate changes on cash and cash equivalents, and restricted cash | 73 | (11) |
| Change in cash and cash equivalents, and restricted cash | 2,242 | (4,146) |
| Cash and cash equivalents, and restricted cash at beginning of the period | 5,627 | 4,502 |
| Cash and cash equivalents, and restricted cash, end of period | $7,869 | $356 |
| Nine-month period ended September 30, | |||
|---|---|---|---|
| 2025 · 2024 | |||
| (Unaudited) | |||
| Supplemental disclosure of cash flow activities: | |||
| (a) Net cash received during the quarter for: | |||
| Interest | $120 | $37 | |
| (b) Non-cash activities: | |||
| Issuance of shares and warrants as settlement of financial liabilities | $ | - | $238 |
| Recognition of right for usage asset against a lease liability | $ | - | $79 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.